Welcome to our dedicated page for Conmed news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on Conmed stock.
CONMED Corporation (NYSE: CNMD) is a medical equipment company in the surgical and medical instrument manufacturing industry. Its products are used in sports medicine procedures and general surgeries across specialties such as orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. The CONMED news feed on this page aggregates company-issued press releases and other coverage related to its operations, strategy and financial performance.
Recent news highlights include updates on portfolio optimization, such as CONMED’s announced intent to exit its gastroenterology product lines and to conclude a distribution agreement for a biliary stent product. The company has linked this decision to a focus on core markets in minimally invasive, robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair. News items also cover quarterly and year-to-date financial results, where CONMED reports net sales by orthopedic and general surgery categories, and by single-use and capital products, along with domestic and international growth metrics.
Investors and observers can also follow governance and leadership developments through this news stream. CONMED has issued releases about changes to its Board of Directors, including the appointment of a new independent director and the resignation of another director to take a leadership role at another organization. The company has also announced a planned transition of its Chief Financial Officer, describing the timing and advisory period associated with that change.
Other news topics include capital allocation decisions, such as the declaration of a quarterly cash dividend and the subsequent authorization of a share repurchase program with suspension of the dividend, as well as participation in healthcare investment conferences where CONMED presents investor materials and financial guidance. Users interested in CNMD can use this page to review these types of announcements over time and to see how the company describes its strategy, operations and financial outlook.
CONMED Corporation (NYSE: CNMD) has announced that Curt R. Hartman, Chair of the Board, President, and CEO, along with Todd W. Garner, Executive VP and CFO, will present at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 2:40 ET. Interested parties can access a live webcast through the Company’s website. CONMED specializes in providing innovative surgical devices for minimally invasive procedures across various medical specialties, including orthopedics and general surgery.
CONMED Corporation (NYSE: CNMD) reported a 4.6% year-over-year increase in sales for Q3 2021, totaling $248.8 million. Domestic sales rose 1.6%, while international sales grew by 8.5%. Diluted EPS was $0.47, up from $0.23 in Q3 2020. Adjusted diluted EPS decreased to $0.80 from $0.88. The company adjusted its full-year revenue guidance to $1.015 billion - $1.025 billion due to ongoing pandemic impacts. Full-year adjusted diluted EPS guidance is now $3.18-$3.23, slightly revised from $3.15-$3.25.
CONMED Corporation (NYSE: CNMD) will release its financial results for the third quarter of 2021 on October 27, 2021, after the market closes. A conference call to discuss these results is scheduled for 4:30 p.m. ET on the same day. Participants can join via phone or through a webcast available on CONMED's website. The call will be re-playable from 7:30 p.m. ET on the same day until 7:30 p.m. ET on November 3, 2021.
CONMED Corporation (NYSE: CNMD) announced that Curt R. Hartman, Chair and CEO, along with CFO Todd W. Garner, will participate in a virtual fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 14, 2021, at 5:00 p.m. ET.
The session will be available for live viewing on the Company’s website, www.conmed.com, and can be replayed later.
CONMED specializes in surgical devices for minimally invasive procedures across various medical fields.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2021, to shareholders of record as of September 15, 2021. This decision reflects the company’s commitment to returning value to shareholders amidst ongoing challenges, including those presented by the COVID-19 pandemic. CONMED specializes in medical technology, offering surgical devices for minimally invasive procedures across various medical fields.
CONMED Corporation (NYSE: CNMD) reported a strong financial performance for Q2 2021, with sales reaching $255.2 million, a 61.7% increase year over year. Domestic revenue surged 64.2%, while international sales climbed 58.6%. Diluted EPS was $0.41, up from a loss of $0.96 in Q2 2020. The company raised its full-year revenue guidance to between $1.015 billion and $1.035 billion and adjusted EPS guidance to $3.15 to $3.25, reflecting confidence in ongoing operational improvements and market recovery.
CONMED Corporation (NYSE: CNMD) is set to report its Q2 2021 financial results on July 28, 2021, after market close. A conference call will be held at 4:30 p.m. ET to discuss the results. Interested parties can join the call by dialing 1-844-889-7792 (domestic) or +1-661-378-9936 (international) with passcode 7138188. The call will also be available via webcast on the CONMED website, and a recording will be accessible from 7:30 p.m. ET on the same day until August 4, 2021.
CONMED Corporation (NYSE: CNMD) declared a quarterly cash dividend of $0.20 per share. This dividend is payable on July 6, 2021, to shareholders of record as of June 15, 2021. CONMED specializes in medical technology, offering surgical devices for minimally invasive procedures across various specialties, including orthopedics and general surgery. For additional details, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) reported first-quarter 2021 financial results, highlighting a sales increase of 8.7% year-over-year to $232.7 million. Domestic revenue rose 4.3%, while international revenue surged 14.3%. Diluted EPS rose 55.0% to $0.31. The company enhanced its 2021 revenue guidance to between $1.0 billion and $1.03 billion, up from $975 million to $1.02 billion. Adjusted diluted EPS guidance is now $3.05 to $3.20, improved from $2.85 to $3.05.
CONMED Corporation (NYSE: CNMD) will report its first-quarter 2021 financial results after market close on April 28, 2021. Management will host a conference call at 4:30 p.m. ET the same day to discuss the results. Investors can participate by dialing 1-844-889-7792 (domestic) or +1-661-378-9936 (international) using passcode 1487002. The call will also be webcast on the company's website, with a replay available one hour post-call. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties.